NTRK1 and prostate carcinoma: Although this approach led to identification of a previously unknown mutation in the receptor tyrosine kinase gene EPHB2 in the DU145 prostate cancer cell line [6], combining GINI and aCGH is not the best strategy for prostate cancer cells.